Steven R. Whittaker

5.7k citations

28 papers · 3.2k indexed · 2 hit papers · h-index 20

Molecular Biology top 5%
Oncology top 2%
Pathology and Forensic Medicine top 2%
Cancer Research top 5%
Computational Theory and Mathematics top 1%

Co-authors: Richard Marais Andrew X. Zhu Caroline J. Springer Paul Workman Arnaud Nourry Jorge S. Reis‐Filho Jahan Hussain Carla Milagre
Topics: Melanoma and MAPK Pathways (16 papers)Cancer Mechanisms and Therapy (10 papers)Protein Kinase Regulation and GTPase Signaling (7 papers)
Cited by: Oncology Molecular Biology Pathology and Forensic Medicine
Journals: Cell Cancer Research Oncogene
Partner nations: United Kingdom United States Germany

In The Last Decade

Steven R. Whittaker

28 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

2010 1.1k citations Carla Milagre, Steven R. Whittaker et al. Cell profile →
The role of signaling pathways in the development and treatment of hepatocellular carcinoma

2010 699 citations Steven R. Whittaker, Richard Marais et al. Oncogene profile →

Peers

Countries citing papers authored by Steven R. Whittaker

Since Specialization

Citations

This map shows the geographic impact of Steven R. Whittaker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven R. Whittaker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven R. Whittaker more than expected).

Fields of papers citing papers by Steven R. Whittaker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven R. Whittaker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven R. Whittaker. The network helps show where Steven R. Whittaker may publish in the future.

Co-authorship network of co-authors of Steven R. Whittaker

This figure shows the co-authorship network connecting the top 25 collaborators of Steven R. Whittaker. A scholar is included among the top collaborators of Steven R. Whittaker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven R. Whittaker. Steven R. Whittaker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer 2021 ·Cellular Oncology ·(unknown),Adam Stewart,Georgios Vlachogiannis,Lisa Pickard,Nicola Valeri,David Cunningham,Steven R. Whittaker,Udai Banerji	5
2	Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600 -Wild-Type Colorectal Cancer 2020 ·Molecular Cancer Research ·(unknown),Adam Stewart,David Cunningham,Udai Banerji,Steven R. Whittaker	19
3	A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer 2020 ·Molecular Cancer Therapeutics ·(unknown),Annette J. Self,Paul A. Clarke,Udai Banerji,Federica Piccioni,David E. Root,Steven R. Whittaker	13
4	Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma 2020 ·BMC Cancer ·Priya Sriskandarajah,Alexis de Haven Brandon,Kenneth Macleod,Neil O. Carragher,Vladimir Kirkin,Martin Kaiser,Steven R. Whittaker	9
5	Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells 2019 ·British Journal of Cancer ·Teresa Delgado‐Goñi,(unknown),(unknown),(unknown),Martin O. Leach,Steven R. Whittaker,Mounia Beloueche‐Babari	24
6	Inhibitors of cyclin-dependent kinases as cancer therapeutics 2017 ·Pharmacology & Therapeutics ·Steven R. Whittaker,Aurélie Mallinger,Paul Workman,Paul A. Clarke	284
7	Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors 2015 ·Molecular Cancer Therapeutics ·Steven R. Whittaker,Glenn S. Cowley,Steve Wagner,Flora Luo,David E. Root,Levi A. Garraway	55
8	A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition 2013 ·Cancer Discovery ·Steven R. Whittaker,Jean‐Philippe Theurillat,Eliezer M. Van Allen,Nikhil Wagle,Jessica Hsiao,Glenn S. Cowley,Dirk Schadendorf,David E. Root,Levi A. Garraway	260
9	Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents 2013 ·Bioorganic & Medicinal Chemistry ·Dan Niculescu‐Duvaz,Ion Niculescu‐Duvaz,Bart M. J. M. Suijkerbuijk,Delphine Ménard,Alfonso Zambon,Lawrence Davies,Jean‐François Pons,Steven R. Whittaker,Richard Marais,Caroline J. Springer	36
10	Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors 2011 ·Bioorganic & Medicinal Chemistry ·Stuart C. Wilson,Butrus Atrash,Clare Barlow,(unknown),Peter M. Fischer,Angela Hayes,Lloyd R. Kèlland,Wayne Jackson,Michael Jarman,Amin Mirza,Francisco J. Moreno,Bernard Nutley,Florence I. Raynaud,Peter Sheldrake,Mike Walton,Robert Westwood,Steven R. Whittaker,Paul Workman,Edward McDonald	26
11	A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF 2010 ·Cancer Research ·Steven R. Whittaker,Delphine Ménard,Richard Kirk,Lesley Ogilvie,Douglas Hedley,Alfonso Zambon,Filipa M. Lopes,Natasha Preece,(unknown),Sareena Rana,Maryou Lambros,Jorge S. Reis‐Filho,Richard Marais,Caroline J. Springer	15
12	The role of signaling pathways in the development and treatment of hepatocellular carcinomabreakdown → 2010 ·Oncogene ·Steven R. Whittaker,Richard Marais,Andrew X. Zhu	699
13	Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds 2010 ·Bioorganic & Medicinal Chemistry ·Dan Niculescu‐Duvaz,Ion Niculescu‐Duvaz,Bart M. J. M. Suijkerbuijk,Delphine Ménard,Alfonso Zambon,Arnaud Nourry,Lawrence Davies,(unknown),Frank Friedlos,Lesley Ogilvie,Douglas Hedley,Andrew K. Takle,David M. Wilson,Jean‐François Pons,(unknown),Richard Kirk,Neus Cantariño,Steven R. Whittaker,Richard Marais,Caroline J. Springer	28
14	Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFbreakdown → 2010 ·Cell ·(unknown),Carla Milagre,Steven R. Whittaker,Arnaud Nourry,(unknown),Nathalie Dhomen,Jahan Hussain,Jorge S. Reis‐Filho,Caroline J. Springer,Catrin Pritchard,Richard Marais	1107
15	BRAF Inhibitors Based on an Imidazo[4,5]pyridin-2-one Scaffold and a Meta Substituted Middle Ring 2010 ·Journal of Medicinal Chemistry ·Arnaud Nourry,Alfonso Zambon,Lawrence Davies,Ion Niculescu‐Duvaz,(unknown),Delphine Ménard,(unknown),Dan Niculescu‐Duvaz,Bart M. J. M. Suijkerbuijk,Frank Friedlos,(unknown),Richard Kirk,Steven R. Whittaker,Richard Marais,Caroline J. Springer	18
16	Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors 2010 ·Journal of Medicinal Chemistry ·Alfonso Zambon,Delphine Ménard,Bart M. J. M. Suijkerbuijk,Ion Niculescu‐Duvaz,Steven R. Whittaker,Dan Niculescu‐Duvaz,Arnaud Nourry,Lawrence Davies,(unknown),Filipa M. Lopes,Natasha Preece,Douglas Hedley,Lesley Ogilvie,Richard Kirk,Richard Marais,Caroline J. Springer	31
17	Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies 2010 ·Science Translational Medicine ·Steven R. Whittaker,Richard Kirk,Robert Hayward,Alfonso Zambon,Amaya Virós,Neus Cantariño,Annette Affolter,Arnaud Nourry,Dan Niculescu‐Duvaz,Caroline J. Springer,Richard Marais	118
18	The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into Mitosis 2007 ·Cell Cycle ·Steven R. Whittaker,Robert te Poele,Florence Chan,Spiros Linardopoulos,Michael I. Walton,Michelle D. Garrett,Paul Workman	54
19	Identification of Inhibitors of the Kinase Activity of Oncogenic V600EBRAF in an Enzyme Cascade High-Throughput Screen 2006 ·SLAS DISCOVERY ·Yvette Newbatt,(unknown),Robert Hayward,Steven R. Whittaker,Richard Kirk,Christopher J. Marshall,Caroline J. Springer,Edward McDonald,(unknown),Richard Marais,Paul Workman,Wynne Aherne	11
20	Low Vision Rehabilitation: A Practical Guide for Occupational Therapists 2006 ·Medical Entomology and Zoology ·Mitchell Scheiman,(unknown),Steven R. Whittaker,(unknown),(unknown)	37

About Steven R. Whittaker

Steven R. Whittaker is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology, having authored 28 papers that have together received 3.2k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (16 papers), Cancer Mechanisms and Therapy (10 papers) and Protein Kinase Regulation and GTPase Signaling (7 papers). The work is most often cited by research in Oncology (1.4k citations), Molecular Biology (2.3k citations) and Pathology and Forensic Medicine (515 citations). Steven R. Whittaker has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Richard Marais, Andrew X. Zhu, Caroline J. Springer, Paul Workman, Arnaud Nourry, Jorge S. Reis‐Filho, Jahan Hussain, Carla Milagre, Catrin Pritchard and Nathalie Dhomen. Their work appears in journals such as Cell, Cancer Research and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact